A federal appeals court on Thursday probed a Boston federal judge’s certification of an antitrust class action challenging AstraZeneca PLC’s “pay for delay” settlements with three generic drug makers.

The U.S. Court of Appeals for the First Circuit heard oral argument in In re Nexium Antitrust Litigation over AstraZeneca’s settlements to delay competing generic gastrointestinal drugs.